Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

BACKGROUND: In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. METHODS: To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Weeber, Fleur, Cirkel, Geert A., Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G.M., Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M., van Stralen, Marijn, Veldhuis, Wouter B., Besselink, Nicolle J.M., Horlings, Hugo M., Steeghs, Neeltje, de Jonge, Maja J., Langenberg, Marlies H.G., Wessels, Lodewyk F.A., Cuppen, Edwin P.J.G., Schellens, J.H., Sleijfer, Stefan, Lolkema, Martijn P., Voest, Emile E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589684/
https://www.ncbi.nlm.nih.gov/pubmed/28903445
http://dx.doi.org/10.18632/oncotarget.16029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589684/
https://www.ncbi.nlm.nih.gov/pubmed/28903445
http://dx.doi.org/10.18632/oncotarget.16029

Ejemplares similares